• Je něco špatně v tomto záznamu ?

STAT3 inhibitor Stattic and its analogues inhibit STAT3 phosphorylation and modulate cytokine secretion in senescent tumour cells

R. Mikyskova, O. Sapeg, M. Psotka, O. Novotny, Z. Hodny, S. Balintova, D. Malinak, J. Svobodova, R. Andrys, D. Rysanek, K. Musilek, M. Reinis

. 2023 ; 27 (4) : . [pub] 20230224

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23003648

Signal transducer and activator of transcription 3 (STAT3) signalling serves an important role in carcinogenesis and cellular senescence, and its inhibition in tumour cells represents an attractive therapeutic target. Premature cellular senescence, a process of permanent proliferative arrest of cells in response to various inducers, such as cytostatic drugs or ionizing radiation, is accompanied by morphological and secretory changes, and by altered susceptibility to chemotherapeutic agents, which can thereby complicate their eradication by cancer therapies. In the present study, the responsiveness of proliferating and docetaxel (DTX)‐induced senescent cancer cells to small molecule STAT3 inhibitor Stattic and its analogues was evaluated using tumour cell lines. These agents displayed cytotoxic effects in cell viability assays on both proliferating and senescent murine TRAMP‐C2 and TC‐1 cells; however, senescent cells were markedly more resistant. Western blot analysis revealed that Stattic and its analogues effectively inhibited constitutive STAT3 phosphorylation in both proliferating and senescent cells. Furthermore, whether the Stattic‐derived inhibitor K1836 could affect senescence induction or modulate the phenotype of senescent cells was evaluated. K1836 treatment demonstrated no effect on senescence induction by DTX. However, the K1836 compound significantly modulated secretion of certain cytokines (interleukin‐6, growth‐regulated oncogene α and monocyte chemoattractant protein‐1). In summary, the present study demonstrated differences between proliferating and senescent tumour cells in terms of their susceptibility to STAT3 inhibitors and demonstrated the ability of the new STAT3 inhibitor K1836 to affect the secretion of essential components of the senescence‐associated secretory phenotype. The present study may be useful for further development of STAT3 inhibitor‐based therapy of cancer or age‐related diseases.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23003648
003      
CZ-PrNML
005      
20230425140758.0
007      
ta
008      
230418s2023 gr f 000 0|eng||
009      
AR
024    7_
$a 10.3892/mmr.2023.12968 $2 doi
035    __
$a (PubMed)36825563
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Mikyskova, Romana $u Laboratory of Immunological and Tumour Models, Institute of Molecular Genetics of The Czech Academy of Sciences, 142 20 Prague, Czech Republic
245    10
$a STAT3 inhibitor Stattic and its analogues inhibit STAT3 phosphorylation and modulate cytokine secretion in senescent tumour cells / $c R. Mikyskova, O. Sapeg, M. Psotka, O. Novotny, Z. Hodny, S. Balintova, D. Malinak, J. Svobodova, R. Andrys, D. Rysanek, K. Musilek, M. Reinis
520    9_
$a Signal transducer and activator of transcription 3 (STAT3) signalling serves an important role in carcinogenesis and cellular senescence, and its inhibition in tumour cells represents an attractive therapeutic target. Premature cellular senescence, a process of permanent proliferative arrest of cells in response to various inducers, such as cytostatic drugs or ionizing radiation, is accompanied by morphological and secretory changes, and by altered susceptibility to chemotherapeutic agents, which can thereby complicate their eradication by cancer therapies. In the present study, the responsiveness of proliferating and docetaxel (DTX)‐induced senescent cancer cells to small molecule STAT3 inhibitor Stattic and its analogues was evaluated using tumour cell lines. These agents displayed cytotoxic effects in cell viability assays on both proliferating and senescent murine TRAMP‐C2 and TC‐1 cells; however, senescent cells were markedly more resistant. Western blot analysis revealed that Stattic and its analogues effectively inhibited constitutive STAT3 phosphorylation in both proliferating and senescent cells. Furthermore, whether the Stattic‐derived inhibitor K1836 could affect senescence induction or modulate the phenotype of senescent cells was evaluated. K1836 treatment demonstrated no effect on senescence induction by DTX. However, the K1836 compound significantly modulated secretion of certain cytokines (interleukin‐6, growth‐regulated oncogene α and monocyte chemoattractant protein‐1). In summary, the present study demonstrated differences between proliferating and senescent tumour cells in terms of their susceptibility to STAT3 inhibitors and demonstrated the ability of the new STAT3 inhibitor K1836 to affect the secretion of essential components of the senescence‐associated secretory phenotype. The present study may be useful for further development of STAT3 inhibitor‐based therapy of cancer or age‐related diseases.
650    _2
$a zvířata $7 D000818
650    _2
$a myši $7 D051379
650    _2
$a fosforylace $7 D010766
650    12
$a transkripční faktor STAT3 $x metabolismus $7 D050796
650    _2
$a exprese genu $7 D015870
650    _2
$a docetaxel $x farmakologie $7 D000077143
650    12
$a cytokiny $x metabolismus $7 D016207
650    _2
$a stárnutí buněk $7 D016922
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sapeg, Olena $u Laboratory of Immunological and Tumour Models, Institute of Molecular Genetics of The Czech Academy of Sciences, 142 20 Prague, Czech Republic
700    1_
$a Psotka, Miroslav $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Novotny, Ondrej $u Laboratory of Immunological and Tumour Models, Institute of Molecular Genetics of The Czech Academy of Sciences, 142 20 Prague, Czech Republic
700    1_
$a Hodny, Zdeněk $u Laboratory of Genome Integrity, Institute of Molecular Genetics of The Czech Academy of Sciences, 142 20 Prague, Czech Republic
700    1_
$a Balintova, Sona $u Laboratory of Immunological and Tumour Models, Institute of Molecular Genetics of The Czech Academy of Sciences, 142 20 Prague, Czech Republic
700    1_
$a Malinak, David $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Svobodova, Jana $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Andrys, Rudolf $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Rysanek, David $u Laboratory of Genome Integrity, Institute of Molecular Genetics of The Czech Academy of Sciences, 142 20 Prague, Czech Republic
700    1_
$a Musilek, Kamil $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, 500 03 Hradec Kralove, Czech Republic
700    1_
$a Reinis, Milan $u Laboratory of Immunological and Tumour Models, Institute of Molecular Genetics of The Czech Academy of Sciences, 142 20 Prague, Czech Republic
773    0_
$w MED00181650 $t Molecular medicine reports $x 1791-3004 $g Roč. 27, č. 4 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36825563 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20230425140755 $b ABA008
999    __
$a ok $b bmc $g 1924367 $s 1189857
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 27 $c 4 $e 20230224 $i 1791-3004 $m Molecular medicine reports $n Mol Med Rep $x MED00181650
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...